Alnylam

Cath Lab Digest
Sep 30, 2024
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals, Inc. News− Echocardiographic and Cardiac Biomarker Data From the HELIOS-B Study Presented Today Support the Potential of Vutrisiran in…
Read more
Alnylam Pharmaceuticals, Inc.
Mar 13, 2024
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health ––…
Read more
Novo Nordisk
Jul 12, 2021
Novo Nordisk puts $1.2B on the table for Prothena's ATTR drug, teeing up Alnylam challenge and cardiovascular expansion
Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…
Read more
alnylam_logo.png
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: Oct 09, 2023 - FDA Cites Insufficient Evidence of Clinical Meaningfulness - - No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
Read more
alnylam_logo.png
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting
- Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR…
Read more
Subscribe to